November 20, 2023 — FDA has a bone to pick with Otsuka, the company that sells Rexulti (brexpiprazole). The agency is taking issue with false advertising by the company for this drug used in schizophrenia and severe depression. To us, this problem of inflated efficacy claims is especially noteworthy because, for people with obesity who may need this drug, […]
October 23, 2023 — It’s a “deficit of information” we should correct, says FDA Commissioner Robert Califf. He is speaking about the gap in information about how to correctly dose drugs for people living with obesity. Karen Weintraub, reporting for USA Today, tells us this gap might mean that doctors are prescribing the right drug at the wrong dose […]
March 29, 2023 — Scientists and regulators at the FDA have identified a critical gap in new drug development and labeling. It is the failure to test new drugs in people with obesity. Where there are differences in clinical responses and safety, labeling – the instructions for safe use – should reflect those differences. But in many cases, they […]
